Your shopping cart is currently empty

Alteplase (Actilyse; Activase) is a recombinant tissue plasminogen activator and serves as a thrombolytic agent, playing a crucial role in treating acute ischemic stroke, pulmonary embolism, acute myocardial infarction, and catheter occlusion. The specifications below refer to the active content of Alteplase, with the effective Alteplase content: total mass ratio = 1:46~1:50, with the actual ratio depending on the batch.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | Alteplase (Actilyse; Activase) is a recombinant tissue plasminogen activator and serves as a thrombolytic agent, playing a crucial role in treating acute ischemic stroke, pulmonary embolism, acute myocardial infarction, and catheter occlusion. The specifications below refer to the active content of Alteplase, with the effective Alteplase content: total mass ratio = 1:46~1:50, with the actual ratio depending on the batch. |
| In vitro | Alteplase (8.3 and 250 μg/mL, 12 hours) significantly reduces activity in human fetal retinal pigment epithelial cells (hfRPE cells). Additionally, Alteplase (8.3 and 250 μg/mL, 0-6 hours) markedly decreases transepithelial resistance in a time-dependent manner and induces cell death in hfRPE cells. The product formulation includes excipients such as L-arginine, phosphate, and polysorbate 80. |
| In vivo | Administering Alteplase (0.9-10 mg/kg, intravenous injection, 20 to 40 minutes after onset or 180 and 240 minutes after onset) is beneficial when given early, within 3 hours of stroke onset, in mice that experienced thromboembolic stroke. However, if administration is delayed for 3 hours or more, it does not provide benefits. |
| Synonyms | Activase, Actilyse |
| Cas No. | 105857-23-6 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.